قارن الطرق

	مؤشر تلف الأوعية الدموية (VDI)	مؤشر نشاط مرض التهاب الفقار اللاصق (BASDAI)
المجال	أمراض الروماتيزم	أمراض الروماتيزم
العائلة	Process / pipeline	Process / pipeline
سنة النشأة	2003	1994
صاحب الطريقة	Exley et al.	Garrett et al.
النوع	Clinician-rated	Patient-reported outcome (PRO)
المصدر التأسيسي	Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Pusey CD, Savage CO. Development and initial validation of the Vasculitis Damage Index (VDI) for systemic vasculitis. Arthritis & Rheumatism. 2003;48(7):2146-2157.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.
الأسماء البديلة	VDI, Vasculitis Permanent Organ Damage Score	BASDAI, BAS-DAI
ذات صلة	4	4
الملخص	The VDI is a clinician-assessed measure of permanent organ damage in patients with systemic vasculitis, including ANCA-associated vasculitis (AAV), polyarteritis nodosa, and other necrotising vasculitides. Introduced by Exley et al. (2003), VDI captures cumulative irreversible damage across organ systems, complementing disease activity measures (such as the Birmingham Vasculitis Activity Score). Systemic vasculitis is characterised by inflammation of blood vessel walls, leading to ischaemia and permanent tissue damage. VDI acknowledges that damage accrues over time and is largely irreversible, making it a prognostically important measure distinct from transient inflammatory activity.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.